Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Reports Smaller Revenues, Higher Losses and a New Toxicogenomics Deal

NEW YORK, Oct. 24-CuraGen today reported slightly smaller revenues and sharply higher net losses for the third quarter of 2002.


The company's loss was $19.9 million for the quarter, or 41 cents per share. For the third quarter of 2001, the company's loss was $11.1 million or 23 cents per share.


Revenues for the quarter were $6 million, down from $6.1 million during the equivalent period last year.


The company spent $21.3 million on R&D this past quarter, up from $17.4 million during the third quarter of 2001.


For further details, see the press release.


CuraGen also announced a new partnership yesterday in which Ono Pharmaceutical will use its genomics-based toxicology screen to evaluate drug compounds.


In an agreement that builds upon a pharmacogenomics deal the two companies struck in 2000, the Japanese pharmaceutical company will use CuraGen's system evaluate and rank early-stage compounds.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.